HFrEF add-on therapy — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — Add spironolactone with renal and electrolyte monitoring
A mineralocorticoid receptor antagonist can improve outcomes in symptomatic HFrEF when renal function and potassium permit use. This makes add spironolactone with renal and electrolyte monitoring the single best answer in this scenario. The other options would either miss the key safety issue, delay appropriate review, or fail to meet the relevant clinical or professional requirement.
Reference: NICE CKS; BNF